The Quality Oncology Practice Initiative (QOPI®) Certification Program continues to expand its reach, certifying the first system within the U.S. Department of Veterans Affairs, the Salisbury VA Health Care System, on October 9.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Rising health care costs, including escalating drug prices, have led to an increased focus by payers on strategies to guide the use of health care resources. As payers search for ways to control the rising cost of care, they often employ “utilization management" (UM) policies, which are payer-imposed practices that may restrict, limit, or deny coverage for certain treatments.
ASCO has submitted comments to the Food and Drug Administration (FDA) applauding its proposed rule to implement the use of new graphic warning labels on cigarette packaging and advertisements. The comments were sent through a letter from ASCO President Howard A. Burris III, MD, FACP, FASCO, to FDA Acting Commissioner Ned Sharpless, MD, on September 19.
A new JCO Precision Oncology article co-authored by CancerLinQ® Deputy Medical Director Wendy Rubinstein, MD, PhD, FACMG, FACP, and CancerLinQ LLC Medical Director Robert S. Miller, MD, FACP, FASCO, published October 1 examines next-generation sequencing in relation to how it can be implemented into the clinical workflow in a practice setting.
Senators Lisa Murkowski (AK), Doug Jones (AL), and Bill Cassidy (LA) introduced S. 2546, the Safe Step Act of 2019, in the U.S. Senate. If enacted into law, the bill would ensure patients with private insurance have reasonable protections against harmful step therapy practices.
At the 2019 ASCO Advocacy Summit, ASCO members from 35 states held more than 160 Congressional meetings, urging Members of Congress to take action to advance policy priorities which improve patient access to cancer care, including clinical trials.
On September 30, President Trump signed into law a Continuing Resolution (CR), which would provide flat funding for federal agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI), through November 21, 2019. ASCO encourages Congress to take action to include the highest increase possible in a full Fiscal Year (FY) 2020 funding package.
Researchers from around the country joined together for two days of learning and collaboration at ASCO’s headquarters in the greater DC metro area for the 2019 ASCO Research Community Forum (RCF) Annual Meeting. On September 22-23, 2019, experts in the field led timely presentations and discussions that coincided with the meeting’s theme of Working Smarter. Working Together.
On September 26, 2019, the Food and Drug Administration approved daratumumab (DARZALEX®, Janssen) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).
In a letter to the Centers for Medicare & Medicaid Services (CMS), ASCO President Howard A. “Skip” Burris III, MD, FACP, FASCO, commented on provisions in the proposed 2020 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) proposed rule that would impact cancer care for Medicare beneficiaries.
The National Cancer Institute (NCI) is sponsoring a quarterly webinar series honoring the legacy of Arti Hurria, MD, in improving the treatment of older adults with cancer. The first webinar titled, Perspectives on Cancer and Aging: Arti Hurria Memorial Webinar Series, will be held on October 7, 2019, from 1:00-2:00 pm ET.
The American Society of Clinical Oncology (ASCO) presented its 2018 Advocate of the Year Award to Alexandra Thomas, MD, for her exceptional contributions and commitment to the society’s policy and advocacy efforts. As a 2017-2018 participant in ASCO’s Leadership Development Program (LDP), Dr. Thomas went above and beyond to improve research and access to treatment for people living with cancer.
ASCO today presented Representatives Ben Ray Luján (NM-3) and Gus Bilirakis (FL-12) with its annual Congressional Leadership Award in recognition of the lawmakers' exceptional, bipartisan commitment to supporting cancer research and treatment. The ASCO award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their cancer care teams.